Diversion & Abuse Resistant Technology (DART)



Genus Lifesciences' Diversion & Abuse Resistant Technology (DART) is a patented technology platform to provide diversion and abuse-deterrent features to abused pharmaceutical products, such as opioid analgesics like Morphine and Oxycodone.

Developed initially to prevent diversion of List 1 Chemicals, such as Pseudoephedrine, Ephedrine and Phenylpropanolamine, into the manufacture of illegal methamphetamine, it was also successfully applied to create abuse-resistant formulations of opioids.


Pre-clinical testing has successfully shown that this technology discourages common methods of product abuse, including intentional over-dosing, nasal snorting and intravenous injection.

Currently there are no ‘immediate-release/short-acting’ opioids on the market, either alone or in combination, that employ both overdose and abuse/diversion deterrent technology, despite overwhelming data demonstrating growing problems with immediate-release oxycodone products.